Cargando…

NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors

PURPOSE: Veliparib is a PARP inhibitor (PARPi) with activity in BRCA 1/2/PALB2-deficient tumors. Preclinical observations reveal topoisomerase inhibitors like irinotecan are synergistic with PARPi irrespective of homologous recombination deficiency (HRD), potentially expanding the role for PARPi. EX...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cecchini, Michael, Walther, Zenta, Wei, Wei, Hafez, Navid, Pilat, Mary Jo, Boerner, Scott A., Durecki, Diane E., Eder, Joseph P., Schalper, Kurt A., Chen, Alice P., LoRusso, Patricia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10292219/ https://www.ncbi.nlm.nih.gov/pubmed/37377610 http://dx.doi.org/10.1158/2767-9764.CRC-22-0485

Ejemplares similares

Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study
por: Munasinghe, Wijith, et al.
Publicado: (2016)

Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model
por: Lemasson, Benjamin, et al.
Publicado: (2016)

A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC)
por: Mizugaki, Hidenori, et al.
Publicado: (2015)

ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts
por: Yuan, Alice L., et al.
Publicado: (2018)

Evaluation of ABT-888 in the amelioration of α-synuclein fibril-induced neurodegeneration
por: Hastings, Lyndsay, et al.
Publicado: (2022)

The PARP inhibitor ABT-888 potentiates darbazine-induced cell death in carcinoids
por: Somnay, Yash, et al.
Publicado: (2016)

Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells
por: Fratangelo, Federica, et al.
Publicado: (2018)

Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma
por: Barazzuol, Lara, et al.
Publicado: (2013)

PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitro hepatocellular carcinoma models
por: Guillot, Clément, et al.
Publicado: (2014)

Radiosensitization of Pancreatic Cancer Cells In Vitro and In Vivo through Poly (ADP-ribose) Polymerase Inhibition with ABT-888
por: Tuli, Richard, et al.
Publicado: (2014)

ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells
por: Balvers, Rutger K, et al.
Publicado: (2015)

Poly (ADP-Ribose) Polymerase Inhibitor, ABT888, Improved Cisplatin Effect in Human Oral Cell Carcinoma
por: Paterniti, Irene, et al.
Publicado: (2021)

Modeling Pharmacodynamic Response to the Poly(ADP-Ribose) Polymerase Inhibitor ABT-888 in Human Peripheral Blood Mononuclear Cells
por: Ji, Jiuping, et al.
Publicado: (2011)

PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression
por: Mariano, Germano, et al.
Publicado: (2015)

Phase 1 dose‐escalation study of single‐agent veliparib in Japanese patients with advanced solid tumors
por: Nishikawa, Tadaaki, et al.
Publicado: (2017)

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours
por: Berlin, Jordan, et al.
Publicado: (2018)

miR-7977 inhibits the Hippo-YAP signaling pathway in bone marrow mesenchymal stromal cells
por: Yoshida, Masahiro, et al.
Publicado: (2019)

Hyperinsulinemia contributes to impaired-glucose-tolerance-induced renal injury via mir-7977/SIRT3 signaling
por: Gao, Zhongai, et al.
Publicado: (2020)

Phase 1 Study of ABT‐751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer
por: Rudek, Michelle A., et al.
Publicado: (2016)

Profile of veliparib and its potential in the treatment of solid tumors
por: Wagner, Lars M
Publicado: (2015)

Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma
por: Jue, Toni Rose, et al.
Publicado: (2017)

miR-888: Hit it when you see it!
por: Bader, Andreas G
Publicado: (2014)

Veliparib Is an Effective Radiosensitizing Agent in a Preclinical Model of Medulloblastoma
por: Buck, Jessica, et al.
Publicado: (2021)

Gingival neoplasms: a multicenter collaborative study of 888 patients in Brazil
por: Santos-Leite, Éder Gerardo, et al.
Publicado: (2023)

miR-888 functions as an oncogene and predicts poor prognosis in colorectal cancer
por: Gao, Su-Jun, et al.
Publicado: (2018)

Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial
por: Maitland, Michael L., et al.
Publicado: (2018)

888. Improving outcomes with revised preoperative universal decolonization protocol
por: Gnass, Silvia I
Publicado: (2020)

888. A Predictive Model for Subtherapeutic Vancomycin Troughs in Adults
por: Crisp, Sarah, et al.
Publicado: (2022)

Effect of the PARP inhibitor veliparib on germ cell tumor cell lines
por: Schmidtova, Silvia, et al.
Publicado: (2022)

Phase 1 dose-escalation study of apatinib and irinotecan in esophageal squamous cell carcinoma patients
por: Jia, Jun, et al.
Publicado: (2021)

Preparation and Characterization of Metformin Hydrochloride — Compritol 888 ATO Solid Dispersion
por: Jagdale, SC, et al.
Publicado: (2011)

Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma
por: Fanucci, Kristina, et al.
Publicado: (2023)

Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors
por: Bartelink, Imke H., et al.
Publicado: (2017)

Blocking PARP activity with the inhibitor veliparib enhances radiotherapy sensitivity in endometrial carcinoma
por: Wang, Jing, et al.
Publicado: (2022)

Synthesis of Veliparib Prodrugs and Determination of Drug-Release-Dependent PARP-1 Inhibition
por: Borgini, Matteo, et al.
Publicado: (2023)

General view downstream from Compass - NA58 experiment in the 888 hall
por: André FROTON
Publicado: (2001)

Comparing Bleeding and Thrombotic Rates in Spine Surgery: An Analysis of 119 888 Patients
por: Pirkle, Sean, et al.
Publicado: (2019)

Splice-acceptor site mutation in p53 gene of hu888 zebrafish line
por: Piasecka, Alicja, et al.
Publicado: (2014)

Complete genome sequence of human pathogen Kosakonia cowanii type strain 888-76(T)
por: Yang, Xue-Jing, et al.
Publicado: (2017)

888 Performance Characteristics and Associated Outcomes for an Automated Surveillance Tool for Blood Stream Infection
por: Ridgway, Jessica P., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ipq0561pce7slc5ojo98l2sfrc